Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin

Article

Abstract: Objective : Recent European Guidelines for Diabetes, Prediabetes and Cardiovascular Diseases introdu

Palabras claves:

Cardiovascular disease, GLP-1-based therapy, Metformin, Morbidity, Mortality

Autores:

Avezum A.J., Basile J.N., Colhoun H.M., Cushman W.C., Dagenais G.R., DIaz R., Dyal L., Ferrannini G., Gerstein H.C., Jansky P., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., Mellbin L., Pais P., PATRICIO LOPEZ -JARAMILLO, PīrCrossed D Sign gs V., Pogosova N., Probstfield J.L., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H.

Fuentes:

google

scopus